Upfront pembrolizumab as an effective treatment start in patients with PD-L1  ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

ConclusionsUpfront pembrolizumab showed efficacy in selected patients with PD-L1  ≥ 50% non-oncogene addicted NSCLC and asymptomatic BMs. Prospective studies should address whether pembrolizumab alone, and deferral of radiotherapy, could be pursued in this patient population.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research